Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.53 |
| ▸ | PDE4A | P27815 | 2/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.47 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.47 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23161334 | 0.93 | GPR119 (0.53) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL23161336 | 0.93 | GPR119 (0.53) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2776116 | 0.90 | GPR119 (0.69) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL29079749 | 0.88 | GPR119 (0.58) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6113438 | 0.88 | GPR119 (0.55) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2764837 | 0.88 | GPR119 (0.55) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL72738 | 0.88 | GPR119 (0.55) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL31726619 | 0.88 | GPR119 (0.62) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL22265825 | 0.87 | GPR119 (0.54) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL3160552 | 0.87 | GPR119 (0.54) | GPR119PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770452-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9487526-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2882722-B1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| EP-2882722-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | Envoy Therapeutics Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014028479-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| EP-2268143-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | Forest Laboratories Holdings Limited (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | GPR119 25/4885PDE4D 588/4885PDE4B 605/4885 |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | GPR119 691/4885PDE4D 1857/4885PDE4B 1818/4885 |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | GPR119 25/4885PDE4D 588/4885PDE4B 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.